{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:37:08Z","timestamp":1795027028025,"version":"4.10.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["GN2485"],"award-info":[{"award-number":["GN2485"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["GN2485"],"award-info":[{"award-number":["GN2485"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S036784\/1"],"award-info":[{"award-number":["MR\/S036784\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N026101\/1"],"award-info":[{"award-number":["MR\/N026101\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R025134\/1"],"award-info":[{"award-number":["MR\/R025134\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S036784\/1"],"award-info":[{"award-number":["MR\/S036784\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N026101\/1"],"award-info":[{"award-number":["MR\/N026101\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asociaci\u00f3n Niemann Pick de Fuenlabrada"},{"name":"Niemann-Pick UK"},{"name":"US National Brain Iron Accumulation Disorders Association"},{"DOI":"10.13039\/501100019256","name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","doi-asserted-by":"publisher","award":["562868"],"award-info":[{"award-number":["562868"]}],"id":[{"id":"10.13039\/501100019256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellcome Trust Institutional Strategic Support Fund\/UCL Therapeutic Acceleration Support (TAS) Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Infantile neuroaxonal dystrophy (INAD) is a rare paediatric neurodegenerative condition caused by mutations in the\n                    <jats:italic>PLA2G6<\/jats:italic>\n                    gene, which is also the causative gene for PARK14-linked young adult-onset dystonia parkinsonism. INAD patients usually die within their first decade of life, and there are currently no effective treatments available. GLP1 receptor (GLP-1R) agonists are licensed for treating type 2 diabetes mellitus but have also demonstrated neuroprotective properties in a clinical trial for Parkinson\u2019s disease. Therefore, we evaluated the therapeutic efficacy of a new recently licensed GLP-1R agonist diabetes drug in a mouse model of INAD. Systemically administered high-dose semaglutide delivered weekly to juvenile INAD mice improved locomotor function and extended the lifespan. An investigation into the mechanisms underlying these therapeutic effects revealed that semaglutide significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways. The expression of mediators in both the apoptotic and necroptotic pathways were also significantly reduced in semaglutide treated mice. A reduction of neuronal loss and neuroinflammation was observed. Finally, there was no obvious inflammatory response in wild-type mice associated with the repeated high doses of semaglutide used in this study.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-17338-1","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T06:04:02Z","timestamp":1660543442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease"],"prefix":"10.1038","volume":"12","author":[{"given":"L.","family":"Poupon-Bejuit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Geard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Faour-Slika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Whaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"17338_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ng1826","volume":"38","author":"NV Morgan","year":"2006","unstructured":"Morgan, N. V. et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 38, 752\u2013754. https:\/\/doi.org\/10.1038\/ng1826 (2006).","journal-title":"Nat Genet"},{"key":"17338_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ana.21415","volume":"65","author":"C Paisan-Ruiz","year":"2009","unstructured":"Paisan-Ruiz, C. et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65, 19\u201323. https:\/\/doi.org\/10.1002\/ana.21415 (2009).","journal-title":"Ann Neurol"},{"key":"17338_CR3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/mds.23221","volume":"25","author":"C Paisan-Ruiz","year":"2010","unstructured":"Paisan-Ruiz, C. et al. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25, 1791\u20131800. https:\/\/doi.org\/10.1002\/mds.23221 (2010).","journal-title":"Mov Disord"},{"key":"17338_CR4","unstructured":"Gregory, A., Kurian, M. A., Maher, E. R., Hogarth, P. & Hayflick, S. J. in GeneReviews((R)) (eds M. P. Adam et al.) (1993)."},{"key":"17338_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ymgme.2014.03.008","volume":"112","author":"MA Illingworth","year":"2014","unstructured":"Illingworth, M. A. et al. PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. Mol Genet Metab 112, 183\u2013189. https:\/\/doi.org\/10.1016\/j.ymgme.2014.03.008 (2014).","journal-title":"Mol Genet Metab"},{"key":"17338_CR6","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/B978-0-444-59565-2.00062-9","volume":"113","author":"N Nardocci","year":"2013","unstructured":"Nardocci, N. & Zorzi, G. Axonal dystrophies. Handb Clin Neurol 113, 1919\u20131924. https:\/\/doi.org\/10.1016\/B978-0-444-59565-2.00062-9 (2013).","journal-title":"Handb Clin Neurol"},{"key":"17338_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/JIM.0000000000000129","volume":"63","author":"W Xu","year":"2015","unstructured":"Xu, W. et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. J Investig Med 63, 267\u2013272. https:\/\/doi.org\/10.1097\/JIM.0000000000000129 (2015).","journal-title":"J Investig Med"},{"key":"17338_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","volume":"13","author":"J Jankovic","year":"2017","unstructured":"Jankovic, J. Parkinson disease: exenatide\u2014a drug for diabetes and Parkinson disease?. Nat Rev Neurol 13, 643\u2013644. https:\/\/doi.org\/10.1038\/nrneurol.2017.140 (2017).","journal-title":"Nat Rev Neurol"},{"key":"17338_CR9","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1093\/brain\/awy220","volume":"141","author":"E Rocha-Ferreira","year":"2018","unstructured":"Rocha-Ferreira, E. et al. Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy. Brain 141, 2925\u20132942. https:\/\/doi.org\/10.1093\/brain\/awy220 (2018).","journal-title":"Brain"},{"key":"17338_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107748","volume":"158","author":"X Yang","year":"2019","unstructured":"Yang, X. et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology 158, 107748. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107748 (2019).","journal-title":"Neuropharmacology"},{"key":"17338_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4 (2017).","journal-title":"Lancet"},{"key":"17338_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda, D. & Foltynie, T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today 21, 802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013 (2016).","journal-title":"Drug Discov Today"},{"key":"17338_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.09.023","volume":"136","author":"D Athauda","year":"2018","unstructured":"Athauda, D. & Foltynie, T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson\u2019s disease. Neuropharmacology 136, 260\u2013270. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.023 (2018).","journal-title":"Neuropharmacology"},{"key":"17338_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","volume":"117","author":"LL Nielsen","year":"2004","unstructured":"Nielsen, L. L., Young, A. A. & Parkes, D. G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117, 77\u201388. https:\/\/doi.org\/10.1016\/j.regpep.2003.10.028 (2004).","journal-title":"Regul Pept"},{"key":"17338_CR15","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58, 7370\u20137380. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00726 (2015).","journal-title":"J Med Chem"},{"key":"17338_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon, S. Semaglutide: first global approval. Drugs 78, 275\u2013284. https:\/\/doi.org\/10.1007\/s40265-018-0871-0 (2018).","journal-title":"Drugs"},{"key":"17338_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14712598.2018.1439014","volume":"18","author":"MS Hedrington","year":"2018","unstructured":"Hedrington, M. S., Tsiskarishvili, A. & Davis, S. N. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Expert Opin Biol Ther 18, 343\u2013351. https:\/\/doi.org\/10.1080\/14712598.2018.1439014 (2018).","journal-title":"Expert Opin Biol Ther"},{"key":"17338_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jcjd.2017.08.242","volume":"41","author":"JA Lovshin","year":"2017","unstructured":"Lovshin, J. A. Glucagon-like peptide-1 receptor agonists: a class update for treating type 2 diabetes. Can J Diabetes 41, 524\u2013535. https:\/\/doi.org\/10.1016\/j.jcjd.2017.08.242 (2017).","journal-title":"Can J Diabetes"},{"key":"17338_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang, L., Zhang, L., Li, L. & Holscher, C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides 71, 70\u201380. https:\/\/doi.org\/10.1016\/j.npep.2018.07.003 (2018).","journal-title":"Neuropeptides"},{"key":"17338_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Zhang, L., Li, L. & Holscher, C. Semaglutide is neuroprotective and reduces alpha-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis 9, 157\u2013171. https:\/\/doi.org\/10.3233\/JPD-181503 (2019).","journal-title":"J Parkinsons Dis"},{"key":"17338_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1006\/mcne.1999.0814","volume":"15","author":"H Tsujino","year":"2000","unstructured":"Tsujino, H. et al. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 15, 170\u2013182. https:\/\/doi.org\/10.1006\/mcne.1999.0814 (2000).","journal-title":"Mol Cell Neurosci"},{"key":"17338_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fnmol.2012.00007","volume":"5","author":"D Hunt","year":"2012","unstructured":"Hunt, D., Raivich, G. & Anderson, P. N. Activating transcription factor 3 and the nervous system. Front Mol Neurosci 5, 7. https:\/\/doi.org\/10.3389\/fnmol.2012.00007 (2012).","journal-title":"Front Mol Neurosci"},{"key":"17338_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molbrainres.2005.03.004","volume":"137","author":"PC Chin","year":"2005","unstructured":"Chin, P. C., Majdzadeh, N. & D\u2019Mello, S. R. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137, 193\u2013201. https:\/\/doi.org\/10.1016\/j.molbrainres.2005.03.004 (2005).","journal-title":"Brain Res Mol Brain Res"},{"key":"17338_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3727\/096368916X694364","volume":"26","author":"Y Zhao","year":"2017","unstructured":"Zhao, Y. et al. GSK-3beta inhibition induced neuroprotection, regeneration, and functional recovery after intracerebral hemorrhagic stroke. Cell Transplant 26, 395\u2013407. https:\/\/doi.org\/10.3727\/096368916X694364 (2017).","journal-title":"Cell Transplant"},{"key":"17338_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1113\/jphysiol.2006.119644","volume":"577","author":"GG Holz","year":"2006","unstructured":"Holz, G. G., Kang, G., Harbeck, M., Roe, M. W. & Chepurny, O. G. Cell physiology of cAMP sensor Epac. J Physiol 577, 5\u201315. https:\/\/doi.org\/10.1113\/jphysiol.2006.119644 (2006).","journal-title":"J Physiol"},{"key":"17338_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s0896-6273(02)00686-4","volume":"34","author":"BE Lonze","year":"2002","unstructured":"Lonze, B. E., Riccio, A., Cohen, S. & Ginty, D. D. Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB. Neuron 34, 371\u2013385. https:\/\/doi.org\/10.1016\/s0896-6273(02)00686-4 (2002).","journal-title":"Neuron"},{"key":"17338_CR27","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2353\/ajpath.2009.090343","volume":"175","author":"H Wada","year":"2009","unstructured":"Wada, H. et al. Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. Am J Pathol 175, 2257\u20132263. https:\/\/doi.org\/10.2353\/ajpath.2009.090343 (2009).","journal-title":"Am J Pathol"},{"key":"17338_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/JIR.S84993","volume":"8","author":"O Yanay","year":"2015","unstructured":"Yanay, O., Bailey, A. L., Kernan, K., Zimmerman, J. J. & Osborne, W. R. Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia. J Inflamm Res 8, 129\u2013135. https:\/\/doi.org\/10.2147\/JIR.S84993 (2015).","journal-title":"J Inflamm Res"},{"key":"17338_CR29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/s41598-017-01952-5","volume":"7","author":"L He","year":"2017","unstructured":"He, L., Law, P. T. Y., Wong, C. K., Chan, J. C. N. & Chan, P. K. S. Exendin-4 Exhibits enhanced anti-tumor effects in diabetic mice. Sci Rep 7, 1791. https:\/\/doi.org\/10.1038\/s41598-017-01952-5 (2017).","journal-title":"Sci Rep"},{"key":"17338_CR30","unstructured":"Blumenreich, M. S. in Clinical Methods: The History, Physical, and Laboratory Examinations (eds rd, H. K. Walker, W. D. Hall, & J. W. Hurst) (1990)."},{"key":"17338_CR31","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1523\/JNEUROSCI.4354-07.2008","volume":"28","author":"K Shinzawa","year":"2008","unstructured":"Shinzawa, K. et al. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci 28, 2212\u20132220. https:\/\/doi.org\/10.1523\/JNEUROSCI.4354-07.2008 (2008).","journal-title":"J Neurosci"},{"key":"17338_CR32","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.neuroscience.2009.05.025","volume":"162","author":"R Kimura","year":"2009","unstructured":"Kimura, R. et al. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K\/Akt\/mTOR\/GCLc\/redox signaling pathway. Neuroscience 162, 1212\u20131219. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.05.025 (2009).","journal-title":"Neuroscience"},{"key":"17338_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000445634","volume":"39","author":"YQ Jiang","year":"2016","unstructured":"Jiang, Y. Q. et al. Geniposide prevents hypoxia\/reoxygenation-induced apoptosis in H9c2 cells: improvement of mitochondrial dysfunction and activation of GLP-1R and the PI3K\/AKT signaling pathway. Cell Physiol Biochem 39, 407\u2013421. https:\/\/doi.org\/10.1159\/000445634 (2016).","journal-title":"Cell Physiol Biochem"},{"key":"17338_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2018.04.010","volume":"676","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Geniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R\/AKT signaling pathway. Neurosci Lett 676, 19\u201326. https:\/\/doi.org\/10.1016\/j.neulet.2018.04.010 (2018).","journal-title":"Neurosci Lett"},{"key":"17338_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","volume":"118","author":"F Bassil","year":"2014","unstructured":"Bassil, F., Fernagut, P. O., Bezard, E. & Meissner, W. G. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. Prog Neurobiol 118, 1\u201318. https:\/\/doi.org\/10.1016\/j.pneurobio.2014.02.005 (2014).","journal-title":"Prog Neurobiol"},{"key":"17338_CR36","doi-asserted-by":"publisher","unstructured":"Wang, L., Feng, L. & Zhang, J. Liraglutide exhibits anti-inflammatory activity through the activation of the PKA\/CREB pathway. J Inflamm (Lond) 16, 21, doi:https:\/\/doi.org\/10.1186\/s12950-019-0225-z (2019).","DOI":"10.1186\/s12950-019-0225-z"},{"key":"17338_CR37","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1128\/MCB.16.10.5546","volume":"16","author":"BE Wilson","year":"1996","unstructured":"Wilson, B. E., Mochon, E. & Boxer, L. M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16, 5546\u20135556. https:\/\/doi.org\/10.1128\/MCB.16.10.5546 (1996).","journal-title":"Mol Cell Biol"},{"key":"17338_CR38","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1194\/jlr.R058701","volume":"56","author":"S Ramanadham","year":"2015","unstructured":"Ramanadham, S. et al. Calcium-independent phospholipases A2 and their roles in biological processes and diseases. J Lipid Res 56, 1643\u20131668. https:\/\/doi.org\/10.1194\/jlr.R058701 (2015).","journal-title":"J Lipid Res"},{"key":"17338_CR39","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/brain\/awv132","volume":"138","author":"KJ Kinghorn","year":"2015","unstructured":"Kinghorn, K. J. et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 138, 1801\u20131816. https:\/\/doi.org\/10.1093\/brain\/awv132 (2015).","journal-title":"Brain"},{"key":"17338_CR40","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.1523\/JNEUROSCI.0345-11.2011","volume":"31","author":"G Beck","year":"2011","unstructured":"Beck, G. et al. Neuroaxonal dystrophy in calcium-independent phospholipase A2beta deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. J Neurosci 31, 11411\u201311420. https:\/\/doi.org\/10.1523\/JNEUROSCI.0345-11.2011 (2011).","journal-title":"J Neurosci"},{"key":"17338_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuroscience.2015.05.023","volume":"300","author":"FM An","year":"2015","unstructured":"An, F. M. et al. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro. Neuroscience 300, 75\u201384. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.05.023 (2015).","journal-title":"Neuroscience"},{"key":"17338_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3389\/fphar.2020.00805","volume":"11","author":"N Nuamnaichati","year":"2020","unstructured":"Nuamnaichati, N., Mangmool, S., Chattipakorn, N. & Parichatikanond, W. Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac\/PI3K\/Akt pathway. Front Pharmacol 11, 805. https:\/\/doi.org\/10.3389\/fphar.2020.00805 (2020).","journal-title":"Front Pharmacol"},{"key":"17338_CR43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14728222.2018.1526925","volume":"22","author":"P Duda","year":"2018","unstructured":"Duda, P. et al. Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opin Ther Targets 22, 833\u2013848. https:\/\/doi.org\/10.1080\/14728222.2018.1526925 (2018).","journal-title":"Expert Opin Ther Targets"},{"key":"17338_CR44","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/189728","volume":"2011","author":"P Salcedo-Tello","year":"2011","unstructured":"Salcedo-Tello, P., Ortiz-Matamoros, A. & Arias, C. GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int J Alzheimers Dis 2011, 189728. https:\/\/doi.org\/10.4061\/2011\/189728 (2011).","journal-title":"Int J Alzheimers Dis"},{"key":"17338_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"E Beurel","year":"2015","unstructured":"Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148, 114\u2013131. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.11.016 (2015).","journal-title":"Pharmacol Ther"},{"key":"17338_CR46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3389\/fgene.2018.00597","volume":"9","author":"PL Babin","year":"2018","unstructured":"Babin, P. L. et al. Infantile neuroaxonal dystrophy: diagnosis and possible treatments. Front Genet 9, 597. https:\/\/doi.org\/10.3389\/fgene.2018.00597 (2018).","journal-title":"Front Genet"},{"key":"17338_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2352-4642(19)30236-6","volume":"3","author":"F Bacha","year":"2019","unstructured":"Bacha, F. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children. Lancet Child Adolesc Health 3, 595\u2013597. https:\/\/doi.org\/10.1016\/S2352-4642(19)30236-6 (2019).","journal-title":"Lancet Child Adolesc Health"},{"key":"17338_CR48","doi-asserted-by":"publisher","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 10, 155. doi:https:\/\/doi.org\/10.3389\/fendo.2019.00155 (2019).","DOI":"10.3389\/fendo.2019.00155"},{"key":"17338_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/neup.12202","volume":"35","author":"H Sumi-Akamaru","year":"2015","unstructured":"Sumi-Akamaru, H., Beck, G., Kato, S. & Mochizuki, H. Neuroaxonal dystrophy in PLA2G6 knockout mice. Neuropathology 35, 289\u2013302. https:\/\/doi.org\/10.1111\/neup.12202 (2015).","journal-title":"Neuropathology"},{"key":"17338_CR50","doi-asserted-by":"publisher","unstructured":"Dupont, W. D. & Plummer, W. D., Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 11, 116\u2013128. doi:https:\/\/doi.org\/10.1016\/0197-2456(90)90005-m (1990).","DOI":"10.1016\/0197-2456(90)90005-m"},{"key":"17338_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1365-2818.1999.00457.x","volume":"193","author":"HJ Gundersen","year":"1999","unstructured":"Gundersen, H. J., Jensen, E. B., Kieu, K. & Nielsen, J. The efficiency of systematic sampling in stereology\u2013reconsidered. J Microsc 193, 199\u2013211. https:\/\/doi.org\/10.1046\/j.1365-2818.1999.00457.x (1999).","journal-title":"J Microsc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17338-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:56:07Z","timestamp":1669341367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17338-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17338"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17338-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13825"}}